Skip To Main Content
Anwaar Saeed on Muck Rack

Anwaar Saeed

As seen in: Nature, Wiley Online Library, MDPI, BioRxiv, The Lancet, Cell Reports Medicine, Dove Medical Press, Healio, HMP Global Learning Network, Future Medicine and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Anwaar

Contact Anwaar, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial

|
By Zev A. Wainberg, Gulam A. Manji, Nathan Bahary, Susanna V Ulahannan, Shubham Pant, David R. Spigel, Nataliya V. Uboha, Paul E. Oberstein, Anwaar Saeed, Ji Kim, Ning WANG, Ben Weeder, Karim Mrouj, Jennifer Scott, Daniel DiRenzo, Matthew Walters, Wilson Wu, Soonweng Cho, Eileen M. O’Reilly, Brandon Beagle, Shravani Shitole, Lisa G. Ensign, Angelo Kaplan, Omar Kabbarah
| Nature Verified
Abstract Quemliclustat potently inhibits CD73, a key enzyme producing immunosuppressive adenosine. In a phase 1b trial (ARC-8), we evaluated safety and efficacy of quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab (anti-programmed cell death protein 1 (PD-1)) in first-line metastatic pancreatic ductal adenocarcinoma (PDAC).
Open in Who Shared Issue with article?

Clinical and molecular characteristics of Class II and III BRAF mutations in colorectal cancer - npj Precision Oncology

|
By Ibrahim Halil Sahin, Ibrahim Şahin, Joanne Xiu, Yasmine Baca, Moh’d Khushman, Axel Grothey, Shafia Rahman, Benjamin A. Weinberg, Sanjay Goel, Mehmet Akce, Vikram C. Gorantla, Emil Lou, Anup Kasi, Anthony Shields, George W. Sledge, John Paul Shen, Anwaar Saeed, Emily Palumbo, Matt Oberley, Mohammedtaki Tejani
| Nature Verified
Abstract Class II and III BRAF mutations are uncommon events, with limited data on their clinical and biological characteristics. We investigated clinical and molecular features of BRAF mutation classes in a total of 24,402 patients with mismatch repair proficient CRC (MMRp). Samples collected between 2006 and 2023 were profiled using next-generation sequencing and whole-transcriptome sequencing.
Open in Who Shared Issue with article?

Metastatic Colorectal Cancer Education Center

|
By Emily Estrada Verified, Anwaar Saeed, Eric Christenson Verified
| Oncology Learning Network Verified
Skip to main content
Open in Who Shared View Duplicates (101) Issue with article?
See all 18 licensed articles (32 Total)